{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T06:11:04Z","timestamp":1787897464577,"version":"build-2784847793"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"10","license":[{"start":{"date-parts":[[2019,9,23]],"date-time":"2019-09-23T00:00:00Z","timestamp":1569196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1017459"],"award-info":[{"award-number":["OPP1017459"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1129600"],"award-info":[{"award-number":["OPP1129600"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>Concentration-QTc modeling was applied to pretomanid, a new nitroimidazooxazine antituberculosis drug. Data came from eight phase 2 and phase 3 studies.<\/jats:p>","DOI":"10.1128\/aac.00445-19","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T12:53:07Z","timestamp":1564491187000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":34,"title":["Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis"],"prefix":"10.1128","volume":"63","author":[{"given":"Hanbin","family":"Li","sequence":"first","affiliation":[{"name":"Certara, Inc., Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Salinger","sequence":"additional","affiliation":[{"name":"Certara, Inc., Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Everitt","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchun","family":"Li","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Del Parigi","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Mendel","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry R.","family":"Nedelman","sequence":"additional","affiliation":[{"name":"TB Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","volume-title":"Global tuberculosis report 2018","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. 2018. Global tuberculosis report 2018. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_3_2","volume-title":"Target regimen profiles for TB treatment: candidates: rifampicin-susceptible, rifampicin-resistant and pan-TB treatment regimens","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. 2016. Target regimen profiles for TB treatment: candidates: rifampicin-susceptible, rifampicin-resistant and pan-TB treatment regimens. World Health Organization, Geneva, Switzerland."},{"key":"e_1_3_3_4_2","unstructured":"Dawson R Harris K Conradie A Burger D Murray S Mendel C Spigelman M. 2017. Efficacy of bedaquiline pretomanid moxifloxacin and PZA (BPaMZ) against DS- & MDR-TB abstr 724LB. Conf Retrovir Opportun Infect Seattle WA 13\u201316 February 2017. http:\/\/www.croiconference.org\/sessions\/efficacy-bedaquiline-pretomanid-moxifloxacin-pza-bpamz-against-ds-mdr-tb."},{"key":"e_1_3_3_5_2","volume-title":"Abstr 49th World Conf Lung Health Int Union Tuberc Lung Dis","author":"Conradie F","year":"2018","unstructured":"Conradie F, Diacon A, Everitt D, Mendel C, Crook A, Howell P, Comins K, Spigelman M. 2018. Sustained high rate of successful treatment outcomes: interim results of 75 patients in the Nix-TB clinical study of pretomanid, bedaquiline and linezolid. Abstr 49th World Conf Lung Health Int Union Tuberc Lung Dis, The Hague, The Netherlands, 24\u201327 October 2018. https:\/\/www.abstractserver.com\/TheUnion2018\/TheUnion2018_Abstracts_Web.pdf."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1108"},{"key":"e_1_3_3_7_2","volume-title":"Sirturo label","author":"Janssen Therapeutics","year":"2012","unstructured":"Janssen Therapeutics. 2012. Sirturo label. Janssen Therapeutics, Titusville, NJ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/204384s000lbl.pdf."},{"key":"e_1_3_3_8_2","volume-title":"Avelox label","author":"Bayer HealthCare Pharmaceuticals, Inc","year":"2010","unstructured":"Bayer HealthCare Pharmaceuticals, Inc. 2010. Avelox label. Bayer HealthCare Pharmaceuticals, Inc., Wayne, NJ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/Label\/2010\/021277s038lbl.pdf."},{"key":"e_1_3_3_9_2","first-page":"21","article-title":"Evolution of the thorough QT\/QTc study","volume":"7","author":"Wheeler W","year":"2010","unstructured":"Wheeler W. 2010. Evolution of the thorough QT\/QTc study. Regulatory Rapporteur 7:21\u201323. https:\/\/www.celerion.com\/wp-content\/uploads\/2012\/01\/Evolution_of_the_Thorough_QT-QTc_study.pdf.","journal-title":"Regulatory Rapporteur"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_3_3_11_2","volume-title":"The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs","author":"ICH","year":"2005","unstructured":"ICH. 2005. The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH, Geneva, Switzerland. https:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Guideline.pdf."},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1542-474X.2003.08413.x"},{"key":"e_1_3_3_13_2","first-page":"353","article-title":"An analysis of the time-relations of electrocardiograms","volume":"7","author":"Bazett H","year":"1920","unstructured":"Bazett H. 1920. An analysis of the time-relations of electrocardiograms. Heart 7:353\u2013370.","journal-title":"Heart"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.2109.1334"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01834-16"},{"key":"e_1_3_3_16_2","unstructured":"Pfizer. 2018. Zyvox label. Pfizer Inc New York NY. http:\/\/labeling.pfizer.com\/showlabeling.aspx?id=649."},{"key":"e_1_3_3_17_2","unstructured":"Sanofi-Aventis U.S. LLC. 2010. Rifater label. Sanofi-Aventis U.S. LLC Bridgewater NJ. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050705s007lbl.pdf."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2012.02.023"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.465"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01354-09"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06125-11"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61080-0"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62002-X"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201410-1801OC"},{"key":"e_1_3_3_25_2","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2016","unstructured":"R Core Team. 2016. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/."},{"key":"e_1_3_3_26_2","unstructured":"Pinheiro J Bates D DebRoy S Sarkar D R Core Team. 2018. nlme: linear and nonlinear mixed effects models. R package version 3.1-137. https:\/\/CRAN.R-project.org\/package=nlme."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00445-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00445-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:37:40Z","timestamp":1645479460000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00445-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1128\/AAC.00445-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00445-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"2019-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00445-19"}}